This trial is evaluating whether Treatment will improve 1 primary outcome and 2 secondary outcomes in patients with Hot Flashes. Measurement will happen over the course of Baseline to Week 12.
This trial requires 600 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"The treatments of moderate or severe vasomotor symptoms include estrogen/progestin-based combined oral contraceptives, estrogens, combined hormone therapy, vaginal estrogen, progestins, or progestogen implants. The combination of oral contraceptives with a progestogen implant has also become available in Europe since the introduction of the Mona Lisa study. Nonestrogen treatment options, including NSAFDs, antiprogestogens, aromatase inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressant therapy, are commonly prescribed to moderately severe cases. For severe cases, antidepressants, combined oral contraceptives, vaginal estrogen, or a progestogen implant may be pursued as a next intervention." - Anonymous Online Contributor
"In this multiethnic population of postmenopausal women, vasomotor symptoms were common, but more common among Hispanics than African Americans. Most women with vasomotor symptoms reported they weren't aware of them, and very few reported they were bothered by them." - Anonymous Online Contributor
"The causes of vasomotor symptoms associated with menopause are not clear. A vasomotor trigger could possibly be a factor that is causing discomfort, but it has not yet been demonstrated that it is the cause of these symptoms." - Anonymous Online Contributor
"The frequency and severity of vasomotor symptoms during menopause can be significantly reduced by taking adequate amounts of estrogen. In addition, estrogen therapy also significantly ameliorates menopause-associated dyslipidemia and ameliorates the dyslipidemia even after menopause." - Anonymous Online Contributor
"Menopause-related VSM-related health-risk behaviors could not be completely interrupted, which can't be completely fixed in this case. Further research is necessary on treatments for menopausal-related VSM." - Anonymous Online Contributor
"[Prevalence of vasomotor symptoms associated with menopause]: Almost half of women will have vasomotor symptoms at some point in their life; of those, about half will be bothered by severe symptoms at some point in their life; and 5% will suffer a severe vasomotor symptom attack during their life." - Anonymous Online Contributor
"The common side effects of treatment for early stage breast cancer were predictable based on the clinical trial results, highlighting the importance of shared-decision making as part of the medical management of breast cancer women. The most common side effect was asthenia with or without nausea and/or fatigue, affecting about half of the women in the trials. The common side effects of treatment included: nausea, loss of appetite, vomiting, abdominal pain, numbness, tingling in fingers or toes, weight gain, decreased ability to think clearly, anxiety and depression in menopause. Patients should review the medical information that accompanies their prescription." - Anonymous Online Contributor
"We can clarify the definition of "treatment" in patients with vasomotor symptoms and treat the definition. The clinical perspective can lead to an integrated approach with both pharmacotherapy, hormonal therapy and surgical treatment for vasomotor symptoms." - Anonymous Online Contributor
"Women with menopausal vasomotor symptoms should be advised that they are not alone and that many women will also have other symptoms, like sleep disturbances, vaginal atrophy, and osteoporosis." - Anonymous Online Contributor
"Although most women treated for vasomotor symptoms used a combination of medication, less than 50% received a monotherapeutic hormone substitution (HRT or AAS). Results from a recent clinical trial confirm that women often use multiple treatments for vasomotor symptoms, including combination therapies." - Anonymous Online Contributor
"More than half of women with vasomotor symptoms as a result of menopause do not have a known cause. Further examinations are necessary to understand what causes what severity of vasomotor symptoms." - Anonymous Online Contributor
"There are many advances in our understanding of vasomotor symptoms and ways to minimize them, and the number of potential treatment options are increasing rapidly. Because not all therapies for menopausal vasomotor symptoms are on the market, we may have to select the option that is easiest to use, is effective, and is well tolerated." - Anonymous Online Contributor